CWM
NAUT icon

CIBC World Markets’s Nautilus Biotechnolgy NAUT Stock Holding History

CIBC World Markets’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,811
Closed -$9.31K – 1792
2025
Q1 		$9.31K Buy
+10,811
New +$16.1K ﹤0.01% 1829

Other funds holding NAUT

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $2.32B AUM 30.12% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

CIBC World Markets's NAUT Position: Q2 2025 in Review

CIBC World Markets sold out of Nautilus Biotechnolgy (NAUT) in Q2 2025, closing a stake of 10,811 shares — an estimated $9.31K sold.

CIBC World Markets first reported a position in NAUT in Q1 2025 and held it in 1 quarter. The position peaked at $9.31K in Q1 2025. 71 funds tracked by Wall St. Rank hold NAUT as of Q2 2025.

  • CIBC World Markets reported no remaining Nautilus Biotechnolgy position as of Q2 2025 after selling out during the quarter.
  • CIBC World Markets sold 10,811 Nautilus Biotechnolgy shares in Q2 2025, an estimated $9.31K.
  • CIBC World Markets first reported a position in Nautilus Biotechnolgy in Q1 2025 and held it in 1 quarter.
  • CIBC World Markets's Nautilus Biotechnolgy position peaked at $9.31K in Q1 2025.
  • 71 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2025.

Based on CIBC World Markets's 13F filing for Q2 2025, filed 14 Aug 2025.